Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine

Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine

Because novel SARS-CoV-2 variants continue to emerge, immunogenicity of XBB.1.5 monovalent vaccines against live clinical isolates needs to be evaluated. We report boosting of IgG (2.1×), IgA (1.5×), and total IgG/A/M (1.7×) targeting the spike receptor-binding domain and neutralizing titers agains...

Full description

Bibliographic Details
Main Authors: Xammy Huu Nguyenla, Timothy A. Bates, Mila Trank-Greene, Mastura Wahedi, Fikadu G. Tafesse, Marcel Curlin
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2024-06-01
Series:Emerging Infectious Diseases
Subjects:
COVID-19
respiratory infections
severe acute respiratory syndrome coronavirus 2
SARS-CoV-2
SARS
coronavirus disease
Online Access:https://wwwnc.cdc.gov/eid/article/30/6/24-0051_article

Internet

https://wwwnc.cdc.gov/eid/article/30/6/24-0051_article

Similar Items